Emmanuel Antonarakis, Clark Endowed Professor of Medicine at Masonic Cancer Center, University of Minnesota, shared a post on X:
“Congrats Laura Sena for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?).”
To which Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, added:
“Congratulations Laura Sena et al.!”
Title: IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer
Authors: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, Nihar J. Mehta, Zeynep Irem Ozay, Anika Begum, Ritika Kundra, Erin Shannon, Shayan S. Nazari, Mark G. Evans, Norm Smith, Andrew Elliott, Benzion Samueli, Samson W. Fine, Jie-Fu Chen, Philip W. Kantoff, Pedro Isaacsson Velho, Hao Wang, David E. Sanin, Eliezer M. Van Allen, Neeraj Agarwal, Wassim Abida, Tamara L. Lotan, Nikolaus Schultz, Emmanuel S. Antonarakis, Laura A. Sena
Other articles featuring Emmanuel Antonarakis and Petros Grivas on OncoDaily.
